Eyenovia (NASDAQ:EYEN) Issues Earnings Results

Eyenovia (NASDAQ:EYEN) posted its earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02, Zacks reports. Eyenovia had a negative return on equity of 1,197.12% and a negative net margin of 114,639.41%. During the same period in the previous year, the business earned ($0.18) earnings per share.

Eyenovia Stock Performance

Shares of Eyenovia stock opened at $0.41 on Thursday. Eyenovia has a one year low of $0.37 and a one year high of $2.57. The firm has a market cap of $26.10 million, a price-to-earnings ratio of -0.56 and a beta of 1.75. The company has a debt-to-equity ratio of 3.72, a current ratio of 0.46 and a quick ratio of 0.27. The stock’s 50-day moving average is $0.50 and its 200-day moving average is $0.72.

Insider Buying and Selling

In related news, CEO Michael M. Rowe bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were acquired at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the completion of the acquisition, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. The trade was a 100.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EYEN has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a report on Wednesday. William Blair upgraded Eyenovia to a “strong-buy” rating in a report on Friday, August 30th.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.